Entos Pharmaceuticals

Entos Pharmaceuticals is a biotech company developing genetic medicines using its non-viral, redosable Fusogenix PLV delivery platform. They are focused on creating muscle-targeting therapeutics, specifically to deliver full-length dystrophin for the treatment of Duchenne muscular dystrophy (DMD). Their Fusogenix PLV platform offers a safe and effective means of delivering nucleic acid therapies.

Funding Round: Strategic Investment

Funding Amount: $1M

Date: 22-May-2025

Investors: CureDuchenne Ventures

Markets: Biotech, Gene Therapy, Healthcare

HQ: Edmonton, Alberta, Canada

Founded: 2016

Website: https://www.entospharma.com

LinkedIn: https://www.linkedin.com/company/entospharmaceuticals/

Twitter: https://twitter.com/entospharma

Instagram:

Facebook: https://www.facebook.com/entospharma